Tag:
ENHANCE trial
Latest Headlines
Latest Headlines
Merck won't change endpoint in new Vytorin trial
Merck resisted a steering committee's recommendation to change the primary endpoint in a new clinical trial of its cholesterol drug Vytorin in chronic kidney patients, three years after an endpoint
Judge refuses to dismiss Schering shareholder suit
Will former Schering-Plough management end up on the witness stand, talking about the controversial Enhance trial? A shareholder suit could force them there--and a federal judge has refused the
Niaspan trounces Zetia, spurring debate
Well, analysts were right about that much-anticipated cholesterol drug study. Abbott Laboratories' Niaspan pill did indeed beat out Merck's Zetia at unclogging arteries, according to study results
Lawsuit: Schering execs sat on Vytorin results
Back when Merck and Schering-Plough finally released the results of their star-crossed cholesterol drug study Enhance in early 2008, industry observers wondered just how much the companies themselves
Merck, Schering settle Vytorin claims for $5.4M
Merck and Schering-Plough got out of 35 state investigations of the Enhance trial only $5.4 million poorer. The drugmakers agreed to pay the states' investigative costs--and that's it. No admission
Judge: CafePharma posts stay in Schering case
It looks as if CafePharma is getting another 15 minutes of fame. A federal judge will allow anonymous postings on the site's forum to remain as evidence in a suit against Schering-Plough. That
Vytorin debate heats up ESC
There's controversy brewing at the European Society of Cardiology meeting in Munich. Today, the now-infamous SEAS study, in which Vytorin not only missed its primary endpoint but appeared to be
Hassan's advice for hard times
When the interview subject is adversity, who better to question than Schering-Plough's Fred Hassan, who's seen his share this year? BusinessWeek chatted with the Schering CEO about dealing with hard
Vytorin, Zetia scrips drop 11% in April
Prescriptions for Vytorin and Zetia, Merck/Schering-Plough's co-marketed cholesterol meds, fell off by 11 percent just during the month of April, to less than 2.5 million from 2.8 million in March.
Should Hassan forfeit $13 million?
Should Fred Hassan ( photo ) give back his bonus? That's what Forbes is asking this week, saying that the
